Duarte, CA, United States of America

Srideshikan Sargur Madabushi


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Srideshikan Sargur Madabushi

Introduction

Srideshikan Sargur Madabushi is an accomplished inventor based in Duarte, CA. He has made significant contributions to the field of cancer treatment, particularly in the area of acute myeloid leukemia (AML). His innovative work focuses on non-invasive imaging and treatment methods that enhance patient care.

Latest Patents

Srideshikan holds a patent for an "Anti-CD33 antibody-guided imaging and treatment of acute myeloid leukemia." This patent discloses a non-invasive PET-CT imaging method for detecting AML or extramedullary disease (EMD) in a subject using a radioactive isotope-labeled anti-CD33 antibody. Additionally, it outlines a PET-CT imaged-guided method for treating AML or EMD. This groundbreaking approach has the potential to improve diagnostic accuracy and treatment outcomes for patients suffering from these conditions.

Career Highlights

Srideshikan is currently associated with City of Hope, a leading research and treatment center. His work at this institution has allowed him to focus on developing innovative solutions for complex medical challenges. His dedication to advancing cancer treatment is evident in his research and patent contributions.

Collaborations

Srideshikan collaborates with esteemed colleagues, including Susanta Kumar Hui and Paul J Yazaki. These partnerships enhance the research efforts and contribute to the development of effective treatment methodologies.

Conclusion

Srideshikan Sargur Madabushi's contributions to cancer treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work exemplifies the importance of research and collaboration in the fight against acute myeloid leukemia.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…